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Abstract
With the worldwide spread of the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) 
resulting in declaration of a pandemic by the World Health Organization (WHO) on March 11, 2020, the 
SARS-CoV-2-induced Coronavirus disease-19 (COVID-19) has become one of the main challenges of our 
times. The high infection rate and the severe disease course led to major safety and social restriction 
measures worldwide. There is an urgent need of unbiased expert knowledge guiding the development of 
efficient treatment and prevention strategies. This report summarizes current immunological data on 
mechanisms associated with the SARS-CoV-2 infection and COVID-19 development and progression to the 
most severe forms. We characterize the differences between adequate innate and adaptive immune 
response in mild disease and the deep immune dysfunction in the severe multi-organ disease. The 
similarities of the human immune response to SARS-CoV-2 and the SARS-CoV and MERS-CoV are 
underlined. We also summarize known and potential SARS-CoV-2 receptors on epithelial barriers, immune 
cells, endothelium and clinically involved organs such as lung, gut, kidney, cardiovascular and neuronal 
system. Finally, we discuss the known and potential mechanisms underlying the involvement of 
comorbidities, gender and age in development of COVID-19. Consequently, we highlight the knowledge 
gaps and urgent research requirements to provide a quick roadmap for ongoing and needed COVID-19 
studies.   
Key words: COVID-19 immunity, SARS, SARS-CoV-2 receptors, COVID-19 comorbidity, COVID-19 multi-
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1. Introduction 
Infections with the novel coronavirus SARS-CoV-2 resulting in COVID-19 development represent the major 
medical and scientific challenges of our time. Knowledge on SARS-CoV-2 infection pathways and 
mechanisms associated with immune defense or immunopathology is growing exponentially, as it is 
indispensable to design the proper diagnostic and therapeutic strategies. However, there are several 
knowledge gaps and urgent unmet research needs in our understating of the current pandemics (Table 1). 
A group of experts in basic and clinical immunology has joined forces under the umbrella of the European 
Academy of Allergy and Clinical Immunology (EAACI) to provide a consensus report on the basic molecular 
and immune mechanisms associated with susceptibility, clinical presentations and severity of COVID-19.
2. SARS-CoV-2 receptors: proven and potential interaction partners 
On the basis of sequence homology, all human coronaviruses have animal origins: SARS-CoV, SARS-CoV-2, 
MERS-CoV, HCov-NL63 and HCoV-229E are considered to have originated from bats,1 whereas HCoV- 
OC43 and HKU1 likely originated from rodents (Fig. 1).2  SARS-CoV-2 has a significant structural similarity 
to SARS-CoV and MERS-CoV and other human and animal coronaviruses.3,4 It has been quickly determined 
that SARS-CoV-2, similarly to SARS-CoV, utilises the membrane bound form of angiotensin converting 
enzyme 2 (ACE2) to enter human cells via its spike protein (S).5 After SARS-CoV-2 has bound ACE2, ACE2 
will be internalized and its membrane expression decreased. Whereas ACE2 is an important regulator of 
bradykinin, its reduced expression in the lung environment results in local vascular leakage leading to 
angioedema in the affected lung tissue.6 The host serine protease TMPRSS2 cleaves spike protein into S1 
and S2 fragments, which enables fusion with the cellular membrane, entrance to the cell and start of the 
replication process.7 In addition to TMPRSS2, other proteins such as furin or human endosomal cysteine 
proteases are potentially capable of cleaving S, such as cathepsin L (CTSL) and cathepsin B (CTSB).8,9  ACE2 
is highly expressed in the lungs, small intestine, kidney and heart, but it is not expressed on innate and 
adaptive immune cells.10-13 As recently shown, SARS-CoV-2 can also use CD147 (also called basigin (BSG) 
or extracellular matrix metalloproteinase inducer (EMMPRIN), to enter T-cell lines, as well as cells of 
epithelial origin, but it is not yet clear if then virus can efficiently replicate or it leads to the cell death14,15 
CD147 is utilized as a receptor by other viruses including SARS-CoV and HIV-1, as well as by malaria to 
enter erythrocytes.16-18 It is, however, not yet clear if SARS-CoV-2 can replicate inside immune cells or just 
infects them and causes cell death. CD147 is a transmembrane immunoglobulin-like receptor, which also 
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as cyclophilins A and B (PPIA and PPIB), S100A9 or platelet glycoprotein VI (GP6).20-23 Its extracellular 
glycosylation sites bind to complex proteoglycans such as syndecan-1.24 CD147 often creates membrane 
complexes with CD44, one of the receptors for hyaluronan, an extracellular matrix component.25 
Coronaviruses incorporate host cyclophilins during their cellular replication cycle, which further enables 
them to bind to CD147.26,27 CD147 is expressed in human airway and kidney epithelium, as well as in 
innate cells (granulocytes, macrophages, dendritic cells (DC), innate lymphoid cells (ILCs) and 
lymphocytes.10 Other receptors potentially utilized by SARS-CoV-2 are CD26 (encoded by DPP4; a receptor 
for MERS-CoV), an important T cell and also epithelial cell receptor, amino peptidase N (ANPEP; a receptor 
for human and porcine coronaviruses),13,28 ENPEP and a glutamyl aminopeptidase 29 , as well as DC-SIGN 
30(Fig.2)
3. Entrance of the virus through epithelial barriers:  COVID-19 pathophysiology 
3.1. Airway epithelium: hotspot for disease development 
In the upper and lower airways ACE2 and TMPRSS2 are highly co-expressed,10-13 but there is no expression 
of SLC6A19, which potentially blocks the access of TMPRSS2 to ACE2 and subsequently reduces active 
infection. 31,32 In the nasal and the pharyngeal epithelium, in goblet and ciliated cell, ACE2 is expressed at 
high levels and co-expressed with TMPRSS2 representing the sites of initial viral replication and a main 
source of infectious particles.10-13,31 The lower airways, bronchial epithelium and type II pneumocytes (AT2 
cells) highly express ACE2 and TMPRSS2, which may provide virus entrance to the lung and lead to COVID-
19 pneumonia. Moreover, CD147, CD26, ANPEP and ENPEP are also expressed in the airway epithelium, 
as well as in many innate and adaptive immune cells, 10,13 both in bronchoalveolar lavage (BAL) and 
peripheral blood (Fig. 3a). 
Once the virus enters the host cell, it releases its RNA into the cytoplasm and uses the host translation 
machinery to translate its polyproteins pp1a and pp1b, also known as replicases and viral essential 
proteases 3CLpro and PLpro. These proteases cleave polyprotein complex into several non-structural 
proteins (Nsp), which together with the viral RNA-dependent RNA polymerase form the replication 
complex, where the negative strand and mRNA for structural proteins (S, nucleocapsid (N), envelope (E), 
and membrane (M)) and accessory proteins for the virus are created.2,33,34 After protein translation, they 
traffic through the ER to the Golgi apparatus, where the mature virions are assembled in budding vesicles 
and are exocytosed from the cell. Inside infected cells, there are several innate immune mechanisms 
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interferons type I (IFN and ), type III, and proinflammatory cytokines.35 Genes encoding these 
interferons form the type-1 (E1) epithelial response profile. Also ACE2 is a typical E1 gene.36 This response 
also includes mechanisms such as the expression of helicases or cytidine deaminases targeting viral RNAs 
(Fig. 3a).
Viruses use various strategies to evade those mechanisms.37 Yet, little is known about SARS CoV-2 antiviral 
responses and evasion strategies of this virus, but likely much can be extrapolated from the SARS-CoV and 
MERS-CoV-based knowledge.35,38 Viral single-stranded RNA (ssRNA), double-stranded RNA (dsRNA) and 
proteins are recognized by cytosolic pattern recognition receptors (PRR), mainly RIG-I/MDA5 and toll-like 
receptors (mainly TLR7/8). This recognition lead to recruitment of MAVS, MyD88 and/or TRIF respectively. 
Eventually IRF3 and IRF7 transcription factors are activated leading to the production of type I interferons 
(IFN- and IFN-), whereas NF-KB and AP-1 transcription factors lead to the production of 
proinflammatory cytokines such as IL-6, IL-8, IL-1, CXCL10 and CCL2.38 
Epithelial cells produce type I and type III IFNs upon viral infection. Type I IFN act through receptors 
expressed in a vast number of cells. In contrast, type III IFNs seem to exert their effect mostly on epithelial 
cells, are less inflammatory and are activated faster than type I IFN. 39,40 IFNs are one of the most potent 
antiviral components of the innate immune response. They work on various levels i.e. blocking viral 
attachment, entry, trafficking, protein production and genome amplification and also viral assembly and 
egress.39 Moreover, IFNs also activate other innate and adaptive immune responses. However, in case of 
COVID-19 these responses seem to be diminished 41 or dysregulated.42 
SARS-CoV and MERS-CoV inhibit IFN signaling on various levels.43 The nsp 16 mediated 2’O methylation of 
viral mRNA cap structure prevents coronaviruses recognition by MDA5.44 The sequestration of viral dsRNA 
within double membrane vesicles (DMVs) also protects coronaviruses from detection through cytosolic 
PRRs 45. Moreover, coronaviruses produce many non-structural proteins which inhibit induction of IFNs 
(inhibition of IRF3 and IRF 7) and/or interferon signaling (inhibition of STAT 1 signaling).43 A reduced 
antiviral response via IFN pathway inhibition, together with an ongoing pro-inflammatory response, 
presumably heightened by increased viral load, may lead to excessive inflammation42 and worsening of 
the disease.  In an animal model of SARS-CoV, a delayed type I interferon response resulted in 
accumulation of inflammatory monocytes/macrophages, leading to elevated lung cytokine/chemokine 
levels, vascular leakage and impaired virus-specific T cell responses.42 A recent study in humans showed 
that SARS-CoV-2 infection induces weak IFN responses from infected pneumocytes, even weaker than in 
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ACE2 is also known to protect mice against acute lung injury. Therefore, it needs to be determined 
whether upregulation of ACE2 after the initial antiviral response is used by SARS-CoV-2 to enhance 
infection, but also if the delay of IFN responses potentially leads to impairment of ACE2-related protection 
against lung injury.
3.2. From oral to rectal mucosa: what we know about the involvement of the gastrointestinal tract in 
COVID-19 
Based on the current knowledge of SARS-CoV-2 receptors’ expression on the epithelial barrier sites, the 
gastrointestinal tract requires special attention. Human ACE2 is homogeneously distributed on the brush 
border of enterocytes across the small intestine and in the lung epithelium.46,47 In the oral mucosa, the 
basal layer of non-keratinized, squamous epithelial cells was reported to be ACE2-positive, while stomach 
epithelial cells and colon enterocytes remained negative.46 TMPRSS2 and TMPRSS4 mediate infection of 
small intestinal epithelial cells.48 These enzymes might additionally be an interesting target for therapeutic 
intervention, since a clinically approved protease inhibitor is available.7 Less is known regarding the 
gastrointestinal distribution of CD147.14 Enteric CD147 seems to play a role in carcinogenesis and 
inflammation,49 which might shed a new light on patients’ group at risk for severe SARS-CoV-2 infections 
and needs further attention. Of note, CD26 expression was reported to be high in ileum and jejunum, low 
in duodenal samples and not detectable in colon epithelial cells (Fig. 3b).50 
Gastrointestinal symptoms like vomiting and diarrhea in COVID-19 are gaining attention.51 In the previous 
SARS outbreak and in MERS patients, gastrointestinal complaints were found in approximately 30% of 
patients. In SARS-CoV-2 infections, diarrhea and abdominal pain occur in 20-50% of COVID-19 patients 
and might even precede onset of respiratory symptoms.52,53 SARS-CoV active replication was detected in 
small intestinal enterocytes54 and enteroids derived from human ileum and colon in case of SARS-CoV-2.48 
This is highly relevant as viral excretion was detected in fecal samples and anal swabs of COVID-19 
patients.55 While first evidence is available that human colonic fluids might rapidly inactivate SARS-CoV-2 
in vitro,47 MERS-CoV was found to resist gastrointestinal fluids simulating conditions with elevated pH 
levels after food ingestion, while the virus rapidly lost infectivity when exposed to an acidic gastric fluid 
simulating fasted state.56 These reports might explain, at least partially, the fact that even though SARS-
CoV-2 RNA was detected in stool samples from patients, the isolates were not infective.57Thus, it remains 
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Further understanding of the relationship between disease and the digestive tract is essential to prevent 
transmission and disease progression as well as to design efficient treatment of COVID-19.
3.3. Skin barrier: more than just matter of wearing protective equipment 
Recent reports indicate that in COVID-19 the skin might also be affected. An Italian and a French study 
reported that 20.4% to 50% of COVID-19 cases, respectively developed nonpruritic, erythematous rashes, 
urticaria or varicella-like lesions affecting the trunk and sometimes the limbs.59,60 In general, the rashes 
occurred 3 days after development of COVID-19 symptoms and the median duration was 8 days.61 In 
addition, acrolated ischemic, self-healing lesions at toes and fingers have been observed mainly in 
children and young adults shortly before COVID-19 symptom appearance.62 To put otherwise healthy kids 
in quarantine upon detection of these lesions might help to prevent infection from spreading. Apparently, 
cutaneous manifestations of COVID-19 are similar to skin rashes observed in other common viral 
infections. There is no evidence that they are related to the severity of the disease or an indication that 
the virus can replicate in the skin. 
Unfortunately, the few studies available so far did not detect SARS-CoV-2 presence in skin lesions, which 
questions if the skin manifestations are indeed infectious or para-infectious driven. Given that ACE2 and 
TMPRSS2, the receptors for SARS-CoV-2 entry into human cells, are absent or weakly expressed in the 
skin,63 para-infectious events seem to be more likely. Furthermore, the possibility of adverse drug 
reactions as causative for skin manifestations in COVID-19 is being strongly considered in certain cases.
Some of the protective measures taken during the SARS-CoV-2 pandemic (use of gloves, masks or goggles) 
can affect the skin. Masks and goggles often induce pressure injury due to not properly fitted material, 
and a study in Chinese health care workers indicated that 71% suffer from skin barrier damage such as 
dryness, scales, papules or erythema.64 Causative is the inevitable hand hygiene procedure - 66.1% stated 
to wash their hands more than 10 times per day and only 22.1% used appropriate skin care products 
afterwards. Moreover, long-term usage of gloves over 6 hours per day is common in health care workers 
leading to overhydration and dysbiosis with damage to the stratum corneum and subsequent skin 
infection or sensitization.65 Thus, proper education regarding the use of skin care products after the hand 
hygiene procedure is essential to protect the skin barrier and prevent further skin complications. 
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4.1. Innate Immunity 
4.1.1. DCs and macrophages  
Monocytes/macrophages and DCs play a crucial role in anti-viral responses by linking innate and adaptive 
immunity. Peripheral activation and accumulation of activated pro-inflammatory 
monocytes/macrophages within lungs has become one hallmark of symptomatic SARS-CoV-2 
infection.42,66-68 In contrast, the exact role of interactions between DCs and SARS-CoV-2 has not been 
determined yet. Previous in vitro experiments showed that different human coronaviruses display either 
high (229E) or poor (OC43) capacities to infect macrophages.69 The efficiency of macrophage infection by 
coronaviruses was negatively correlated with IFN- production.69 In COVID-19 patients, ACE2 expression 
was detected on both lymph node-associated CD68+ macrophages and tissue-resident CD169+ 
macrophages.70 It needs to be addressed, however, whether other proven and potential SARS-CoV-2 
receptors, such as CD147 or CD209 (DC-SIGN), both being expressed by monocytes/macrophages and DCs 
can facilitate viral entry to these cells.14,30,71,72 Recently, SARS-CoV-2 particles were found in macrophages, 
but it remains elusive whether these findings were an effect of active cellular infection or just the 
consequences of physiological phagocytosis. It is tempting to speculate that SARS-CoV-2, similarly to HIV, 
can use macrophages as a Trojan horse contributing to viral spread.70,73 Regardless of the exact 
mechanism of viral entry, both previously described coronaviruses and the new SARS-CoV-2 can trigger 
NLRP3 inflammasome activation in monocytes/macrophages, production of high levels of 
proinflammatory mediators such as IL-6, GM-CSF, IL-1, TNF, CXCL-8 or CCL-3, enhanced cell death and 
lead to the cytokine storm also known as Cytokine release syndrome (CRS) (Fig. 4)74. Some of these 
cytokines (i.e. IL-6) are mainly secreted by macrophages 68,75-78 and the evidence of macrophage activation 
syndrome has been reported.79 Thus, beneficial effects of anti-IL-6R treatment on COVID-19 outcomes 
indicate that therapies targeting macrophage-related activities can become promising means to inhibit 
the inflammatory storm in the course of coronavirus disease.80 Overloaded, activated and subsequently 
dying macrophages might contribute to an increase in the levels of plasma ferritin and profound 
dysregulation of iron metabolism81,82. High ferritin levels are common clinical findings in patients with 
severe COVID-19 83.
 
4.1.2. Neutrophils and eosinophils 
Neutrophils are one of the predominant lung infiltrating leukocytes in severe SARS-CoV-2 infection, and 
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patients showed neutrophil infiltration in pulmonary capillaries and neutrophil extravasation into the 
alveolar space.85,86 Under neutrophil activating conditions, such as those occurring during systemic 
inflammation (CRS), neutrophil extracellular traps (NETs) can be released. Although this is a way to 
ensnare pathogens, NET formation is linked to pulmonary diseases, particularly acute respiratory distress 
syndrome (ARDS). Severe COVID-19 conditions with uncontrollable progressive inflammation presumably 
induce an intense crosstalk between neutrophils releasing NETs and IL-1β secretion from macrophages, 
which is the driving force in further complications.85    
Although eosinophils have protective effects in different viral infections, the eosinophil response towards 
SARS-CoV-2 is incompletely understood.87 A significant amount of COVID-19 patients present 
eosinopenia,88,89 although it is not reported in all cohorts.90 The pathophysiological mechanism  of 
eosinopenia in COVID-19 patients is not clear but may be related to increased apoptosis, less 
eosinophilopoiesis, and decreased eosinophil egression from the bone marrow.91 Increased tissue 
migration  is unlikely because eosinophils infiltration was not found in pulmonary tissue of COVID-19 
patients,92 but further research is needed. 
4.1.3. ILC and NK cells 
ILC are effector cells that respond to environmental cytokines and regulate immune responses.93,94 Type 1 
ILC include IFN-γ producing subtypes and natural killer (NK) cells. Limited data are available on the role of 
ILC in relation to COVID-19, but it has been shown that ILC1-ILC3 express CD26, CD147, cyclophilins and 
theirs interaction partners.10 Data on the numbers of NK cells in patients with COVID-19 are varied. Some 
studies reported no differences in NK cell counts compared to healthy controls,95,96 while one study found 
increased numbers of NK cells and suggested a role for NK cells in the CRS.97 In contrast, other studies 
showed low98 or considerably decreased numbers of NK cells in patients with SARS-CoV-2 infection, which 
was more prominent in severe cases.99-101 After successful treatment, the numbers of NK cells restored to 
the normal levels with reduced expression of NKG2A.101 
Functional exhaustion of NK cells and CD8+ T cells was described in relation to severe SARS-CoV-2 
infection (Fig 4). Exhausted NK and CD8+ T cells expressed CD94/NK group 2 member A (NKG2A), which 
functions as an inhibitory receptor, and showed diminished production of CD107a, IFN-γ, IL-2, granzyme 
B, and TNF-α.101 During infection IFN-γ induce expression of the non-classical human leukocyte antigen E 
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monoclonal antibodies (Monalizumab) prevents the binding of HLA-E, which may be a target for COVID-19 
therapy. 
4.1.4. Complement and SARS-CoV-2 
The complement system is engaged in both coagulation and inflammatory pathways. Histologic and 
immunohistochemical analysis of lung and skin have been conducted in patients with COVID-19-induced 
ARDS. The typical pulmonary findings for ARDS were accompanied with significant deposits of terminal 
complement components C5b-9 (membrane attack complex), C4d, and mannose binding lectin (MBL)-
associated serine protease (MASP)2, in the microvasculature.103 The biopsies of both damaged and 
normally-appearing skin revealed a pauci-inflammatory thrombogenic vasculopathy, with deposition of 
complement products C5b-9 and C4d.103 The authors conclude that a subset of sustained, severe COVID-
19 patients may be defined by a type of catastrophic microvascular injury syndrome mediated by 
activation of complement pathways and an associated procoagulant state. Further, C3 deficient mice 
developed significantly less respiratory dysfunction despite viral loads deposited in the lung. These data 
indicate that SARS-CoV-mediated disease is largely immune driven and complement activation regulates a 
systemic proinflammatory response to SARS-CoV infection.104 Most recently, the placentas from 5 healthy 
newborns (all negative for viral RNA and spike protein) of COVID-19 positive mothers revealed vascular 
thrombosis without complement deposition,  supporting COVID-19's systemic procoagulant effects 
unrelated to systemic complement activation.105 
4.1.5. Trained immunity 
Stimulation of innate immune cells with specific microbial antigens induces long lasting epigenetic and 
metabolic re-programming leading to enhanced responses upon a second challenge by the same or 
unrelated microbial insults, a process coined as “trained innate immunity”.106,107 As a consequence, 
Trained Immunity-based Vaccines (TIbV) able to induce potent responses against both specific and non-
specific antigens contained in the formulation has emerged as a novel concept in vaccinology.107 TIbV 
might be especially relevant when conventional vaccines are not available, as it is the case for SARS-CoV-
2. One of the best examples about trained immunity is the influence of BCG vaccination on unrelated 
pathogens.106 BCG seems to induce nonspecific responsiveness to infections both at the level of trained 









This article is protected by copyright. All rights reserved
increased production of pro-inflammatory cytokines, increased protection against infections and reduced 
mortality.109 Increased expression of PRRs in monocytes isolated from peripheral blood mononuclear cells 
(PBMCs) of healthy individuals 1 year after BCG vaccination has marked the importance of trained 
immunity.108 Although further studies are required, lower number of cases and deaths per population 
during COVID-19 pandemic seem to be reported in countries with BCG vaccination programs than those 
that did not have or ceased it, which could be attributed to potential BCG vaccination-induced trained 
immunity effects.110,111 Trials assessing the efficacy of BCG vaccination in populations at high risk of 
infection or with a high risk of mortality, such as hospital staff working in close contact with COVID-19 
patients or older individuals, are currently being performed in the Netherlands, Australia and Greece.112 
Future research and clinical trials are needed to demonstrate whether novel TIbV might represent a 
suitable strategy for the prevention and treatment of SARS-CoV-2 infection.
4.2. Adaptive immunity 
4.2.1. T cell-related mechanisms: lymphopenia, T cell over-activation and T cell exhaustion 
Cytotoxic CD8+ T cells directly neutralize infected cells, and CD4+ T cells aid B cells to initiate humoral 
responses (Fig 4) 113. T cells are instrumental in developing immunological memory in the form of virus 
specific CD8+ and CD4+ T cells as shown in case of SARS-CoV.114-116 In fact, SARS-CoV specific CD8+T cells 
have been detected in humans up to 11 years post-infection, which is longer than the specific antibodies 
116. SARS-CoV-2-specific CD8+ and CD4+ T cells were also recently identified in ~70% and 100% of COVID-19 
convalescent patients, respectively. CD4+ T cells responded to spike (S) protein, which correlated with the 
magnitude of the anti-SARS-CoV-2 IgG and IgA titers. Importantly, SARS-CoV-2 reactive CD4+ T cells were 
also detected in ~40-60% of unexposed individuals, suggesting cross-reactive T cell recognition between 
circulating ‘common cold’ coronaviruses and SARS-CoV-2 117, which was confirmed by others.118 Profound 
lymphopenia, with the subsequent shifts in the T cell subsets composition, is often reported in SARS-CoV-
2 infection, similarly to SARS-CoV and some other viruses.96,100,119 Total numbers of CD4+ T cells and CD8+ T 
cells are below normal levels in most COVID-19 patients, with the lowest numbers in the severe cases. 
Moreover, the number of Treg cells is also decreased,100 whereas a recent case report of non-severe 
COVID-19 showed a progressive increase in the proportion of CD4+CXCR5+ICOS+PD-1+ circulating follicular 
helper T (TFH) cells.98 Delayed development of adaptive responses, together with prolonged virus 
clearance has been reported in cases of severe SARS-CoV-2 infection (Fig 4).120 Unfortunately, the 
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cells can be infected through highly expressed CD14714,15 or potentially through CD26, as ACE2 expression 
on lymphocytes is very low 10, except in certain tissue-derived T cells.121 It is yet unclear whether such 
infection is the reason of the death of infected T cells. Secondly, as in the case of SARS-CoV, an alteration 
in the antigen presenting cells (APCs) function and subsequent impairment of T cell priming might lead to 
an inefficient/delayed formation of virus-specific T cells 122-124. Finally, also a high cytokine response from 
the infected cells might induce apoptosis of T cells 125. The causes of lymphopenia need to be extensively 
studied, as it correlates with the higher risk of severe disease and increased length of hospitalization 
126,127. In addition to decrease in numbers, there are also other defects reported in the function of T cell 
subsets in SARS-CoV-2 infection. In severe pneumonia in COVID-19 patients, it has also been shown that 
highly cytotoxic, activated CD8+ T cells and Th17 cells, can also participate in the CRS, together with 
macrophages and epithelial cells 119. Highly activated T cells participating in viral infection often acquire an 
exhausted phenotype. Surviving T cells appear functionally exhausted with elevated levels of PD-1128 . The 
increased expression of PD-1 and Tim-3 on CD8+ T cells was found to progress with the infection. T cell 
exhaustion is a reversible process where a decrease in antigen availability, achieved either through the 
gradual resolution of the infection or intervention strategy, has led to exhausted T cells regaining their 
functions129.
4.2.2. B-cell-related mechanisms and antibody-responses 
Human SARS-CoV-2 infection activates mechanisms of B and T cell immunity that result in the generation 
of neutralizing antibodies.130 Initially, B cells appear to recognize SARS-CoV-2 through the nucleocapsid 
protein, which induces their activation and subsequent interaction with cognate CD4+ T cells. The 
antibody response is mounted 4-8 days after the onset COVID-19 symptoms and dominated by IgM.131 
This initial IgM-response is followed by IgA and then IgG production (10-18 days). 
The development of mucosal IgA likely prevents SARS-CoV-2 re-infection while circulatory IgA may 
contribute to systemic SARS-CoV-2 neutralization and to dampen inflammation during active infection (Fig 
4).132 The extent and quality of the IgG response to neutralize SARS-CoV-2 is critical. Based on previous 
SARS-CoV infection reports, SARS-CoV-2-neutralizing IgG antibodies should be specific for the S protein 
and detected in serum at 2-3 weeks post-infection.133,134 For that reason, human convalescent serum 
transfer has been proposed for the prevention and treatment of COVID-19 patients.135 In fact, and a 
number of clinical trials have recently reported its therapeutic value in COVID-19.52,55,136,137 However, low 
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binding. This mechanism may induce the release of inflammatory cytokines and contribute to the CRS 
reported in some severe COVID-19 patients.138  
In a recent pre-print study, single-cell RNA sequencing (scRNA-seq) of PBMCs of 7 patients hospitalized 
with confirmed COVID-19 and 6 healthy controls was performed.139 Heterogeneous interferon-stimulated 
gene (ISG) signature, HLA class II downregulation, and a novel B cell derived granulocyte population were 
reported in patients with acute respiratory failure requiring mechanical ventilation. The putative 
contribution of this intriguing B cell population to COVID-19 pathology remains to be elucidated. 
A central issue of B cell immunity to SARS-CoV-2 is the duration of the antibody (IgG) response once the 
infection is cleared, as well as the ability for SARS-CoV-2 specific memory B cells to expand, or replenish, 
the plasma cell compartment upon re-infection. Given that long-lived plasma cells and high-affinity 
memory B cells are thought to be germinal center-dependent,140 it is important to characterize the 
antibody and B cell memory repertoire (affinity, number of mutations, clonal origin, etc.) of asymptomatic 
patients and patients that have recovered from COVID-19. The rapid peak of viral load detected in COVID-
19 patients,141,142 as compared to SARS-CoV, may accelerate plasma cell differentiation, 143 thus limiting 
the germinal center phase and the degree of long-term immunity protection. 
4.3. Multi-organ involvement in severe COVID-19
4.3.1. Lung pathologies in COVID-19
It has yet to be determined whether SARS-CoV-2 shows significantly more pronounced lung tropism than 
other respiratory viruses. COVID-19-associated viral pneumonia is relatively frequently complicated by 
ARDS. Lung CT images of COVID-19 pneumonia patients revealed mostly diffuse patchy ground glass 
opacities under the pleura with partial consolidation which, in clinically improving individuals, can be 
further absorbed and followed by formation of fibrotic tissue.144 Postmortem analysis of COVID-19 
patients revealed extensive alveolar damage complicated by the formation of hyaline membranes, diffuse 
remodeling of alveolar wall and accumulation of immune cells (mostly macrophages) infiltrating air 
spaces.119,145 Macrophages accumulating in lungs secrete type I and type III IFNs that enhance local 
antiviral defenses in surrounding epithelial cells. Lung-associated macrophages contribute to 
development of CRS by producing IL-6 and IL-1β, cytokines promoting further recruitment of cytotoxic T 
cells and neutrophils. In consequence, activated neutrophils produce reactive oxygen species and 
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not prevent from continuous lung damage, development of frequently progressive and irreversible 
fibrotic consequences.147 At this relatively early phase of the pandemic, the exact fraction of COVID-19 
patients burdened with persistent fibrotic interstitial lung disease cannot be precisely determined. 
Nevertheless, available and novel anti-fibrotic therapies should also be considered as candidate strategies 
to manage post-COVID-19 long-term lung fibrosis.148
4.3.2. Myocardial and endothelial damage: an immunological perspective on cardiac presentation of 
COVID-19 
Cardiac injury is a prominent feature in COVID-19 developed by a considerable proportion of patients, and 
is associated with an increased mortality.149 The pathogenesis of COVID-19 in the cardiovascular system 
likely results from a combination of several mechanisms such as direct viral toxicity, systemic CRS-
mediated and stress-related injury. These mechanisms promote cardiomyocyte and endothelial apoptosis, 
endothelial shedding, plaque destabilization and increase wall shear stress, leading to myocarditis, 
endotheliitis, ischemia, cardiac arrhythmias and hypercoagulability.  ACE2 is highly expressed on 
cardiomyocytes and endothelial cells, possibly facilitating direct viral damage. However, it is unknown 
whether vascular derangements in COVID-19 patients are due to endothelial cell involvement by the virus. 
A recent study found that endothelial cells can be infected by SARS-Cov-2, as postmortem analysis of 
kidney by electron microscopy revealed viral inclusion structures within endothelial cells.150 The post-
mortem histology from patients with multiorgan failure in COVID -19 showed endothelitis in the lung, 
heart, kidney, liver and small intestine, with an accumulation of inflammatory cells associated with 
endothelium 150. These findings suggest that the endotheliitis may be a combination of direct 
consequence of the viral involvement (i.e. presence of intracellular viral bodies) and the host 
inflammatory response (Fig. 5).
In cardiomyocytes SARS-CoV-2 appears to downregulate ACE2 and diminish its cardioprotective role, 
promoting left ventricular failure and hypertrophy, as well as pro-thrombotic and pro-oxidant pathways 
151. Few cases documented myocarditis with diffuse T-lymphocytic inflammatory infiltrates with interstitial 
oedema and without fibrosis, suggesting an acute inflammatory process. A recent study presenting data 
from autopsy series also demonstrated SARS-CoV-2 viral load in heart tissue 152-154. Since SARS-CoV-2 may 
predispose patients to coagulopathies with clinical manifestations ranging from arterial and venous 
embolisms to disseminated intravascular coagulation, with very poor prognosis, early prophylactic 
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imbalanced host immune response and systemic inflammation are proposed as important mechanisms of 
myocardial/endothelial injury. 
4.3.3. Coagulation parameters in COVID-19 patients 
Abnormal coagulation parameters such as mild thrombocytopenia, prolonged prothrombin time, 
disseminated intravascular coagulation156-158 and elevated D-dimers are seen in 36% to 43% of COVID-19 
patients.157,159  In a meta-analysis of 4 published studies, higher D-dimers were found in patients with 
more severe COVID-19.159 Also, thrombocytopenia was reported to be associated with more severe 
COVID-19 and increased risk of death (Fig. 5).158,160 In a trial of severe COVID patients (n=99), 
anticoagulant therapy (e.g. low molecular weight heparin) was associated with better prognosis.161
Activation of endothelium, platelets, and leukocytes leads to enhanced local and systemic production of 
thrombin, which in turn leads to deposition of fibrin, microangiopathy, and eventual organ damage. Both 
pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) 
initiate these processes.162  In 16 patients with severe COVID-19 a correlation between IL-6 and fibrinogen 
levels was found, supporting a link between hyperinflammation and increased venous thromboembolism 
(VTE) risk.163 
Although thrombocytopenia has been implicated in patients infected with SARS-CoV-2, the association 
between platelets and the disease mortality is not clear. In COVID-19 patients from Wuhan, China, 
platelet count increase was an independent risk factor reversely associated with in-hospital mortality, as 
an increase of 50x109/L platelets was associated with a 40% decrease in mortality158. Another study of 
548 patients from China found that while platelet levels were decreased when hospitalization for COVID-
19, platelet levels increased in survivors over time, but maintained lower levels or dropped significantly 
over time in non-survivors.164  Thus, baseline platelet levels and changes over time appear to be 
associated with subsequent mortality and monitoring platelet levels is important in predicting prognosis 
of patients with SARS CoV-2 infection.
4.3.4. Neurological disease presentation
Together with the choroid plexus, the blood-brain-barrier protects the brain from invading 
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barriers,166 especially in cases of systemic inflammation167 causing potential alterations of the central 
nervous system (CNS). In particular, coronaviruses might exhibit neurotropic properties,168 and  SARS-CoV 
was detected in human brain 169,170. Of interest, ACE2 is expressed in the human brain 46. Based on the 
knowledge from animals studies, SARS-CoV can enter the brain via the olfactory nerve leading to a rapid, 
transneuronal spread to connected areas of the brain.171 As SARS-CoV infects immune cells, the virus 
might penetrate the CNS also via the hematogenous route.170 
In the current COVID-19 outbreak, a few case reports described meningitis/encephalitis or COVID-19–
associated acute necrotizing hemorrhagic encephalopathy with or without SARS-CoV-2 RNA detected in 
the cerebrospinal fluid.172,173 Moreover, autopsies of patients with COVID-19 showed cerebral hyperemia 
and edema with degeneration of some neurons.174 In a study on COVID-19 patients from Wuhan hospitals, 
78 out of 214 patients had neurological manifestations especially in severe infections. Some patients had 
only neurological manifestation without typical COVID-19 symptoms.175 In addition, olfactory and 
gustatory dysfunctions are often reported in patients with COVID-19,176-178 which might be due to direct 
effects on the nervous system. 
4.3.5. COVID-19-related kidney failure 
Recent evidence indicates that kidney injury occurring during SARS-CoV-2 infection can result not only 
from CRS and on-going sepsis but also from direct virus-induced impairment.179,180 In fact, ACE2 is highly 
expressed on renal tubular cells.181 Clinical observations of COVID-19-related kidney damage have been 
confirmed by an elegant experiment demonstrating that SARS-CoV-2 can directly infect 
human kidney organoids.182 Moreover, this infection led to further efficient shedding of progeny viruses 
capable of infecting Vero E6 cells. This finding suggests that kidneys are an active player in the process of 
viral spread rather than only a site of virus-induced tissue damage. The process of kidney infection by 
SARS-CoV-2 was significantly, but not completely inhibited by human recombinant soluble ACE2, which 
indicates that there might be other than ACE2 receptors accounting for the entry of SARS-CoV-2 to kidney 
cells.182 The putative candidate can be CD147 being highly expressed on proximal tubular epithelium. 
CD147 together with one of its ligands, cyclophilin, plays a crucial role in renal inflammation and renal 
fibrosis.183 Moreover, cyclophilins efficiently control the process of coronavirus replication.184 Thus, 
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4.4. Multi-morbidities as a risk factor for severe COVID-19
Multi-morbidities are associated with the severe course of COVID-19. A meta-analysis including 1,558 
patients with COVID-19 showed as independent risk factors chronic obstructive pulmonary disease 
(COPD) (OR: 5.97), cerebrovascular disease (OR:3.89), type 2 diabetes mellitus ((T2DM) (OR: 2.47), and 
hypertension (OR: 2.29).185,186 In the nation-wide report from China including 1590 patients with COVID-19 
one comorbidity was present in 25.1% and two or more comorbidities in 130 8.2% patients (Fig 6).187 
Several mechanisms directly linked to the underlying pathological condition can contribute to the 
unfavorable clinical outcome. A recent study suggested that hypertension and diabetes resulted in 
delayed clearance of SARS-CoV-2.188 The relationship between the immune dysfunction in patients with 
multi-morbidities and infection with SARS-CoV-2 was not specifically evaluated. A transgenic diabetic 
mouse model expressing human CD26 had more severe disease together with a dysregulated immune 
response following infection. A delayed and decreased recruitment of CD4+ T cells and inflammatory 
monocytes and macrophages into the lung tissue and a more prominent Th17 response was oberved.189 
Interestingly, obesity is changing the expression profile of SARS-CoV-2 receptors10.
Metabolic induced low-grade systemic inflammation, as in obese patients,190 facilitates an enhanced 
release of cytokines upon an acute trigger such as viral infection. As the human endocrine pancreas 
expresses ACE2, the coronavirus might enter islets and cause acute β-cell dysfunction, leading to acute 
hyperglycaemia and transient T2DM 191. A mathematical model showed that the insulin resistance, 
advanced glycan endproduct (AGE)-Receptor of AGE (RAGE) signaling pathway in diabetic complications 
and the adipocytokine signaling pathway were found in all fatal comorbidities of COVID-19.192 In addition, 
AGEs can induce monocyte CD147 expression, an effect mediated by inflammatory pathways and RAGE.193 
CD147 is highly expressed in patients with diabetic complications such as nephropathy, retinal neuropathy 
and vasculopathy and was associated with chronic renal failure of other causes.
COPD and ongoing smoking contribute to COVID-19 severity 194. COPD and active smokers had 
significantly increased expression of ACE2 and its gene expression inversely related to the lung function, 
suggesting a dose-dependent response.195 
Multimorbidity is also associated with elevated levels of plasminogen. Plasmin, and other proteases, may 
cleave a newly inserted furin site in the S protein of SARS-CoV-2, extracellularly, which increases its 
infectivity and virulence. Hyperfibrinolysis associated with plasmin leads to elevated D-dimer in severe 
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4.5. Sex and ageing as a risk factor for COVID-19 course 
The increased vulnerability of males compared to females to severe COVID-19 has been reported during 
the pandemic. A direct endocrine link is involved as androgen receptor activity is required for the 
transcription of TMPRSS2 gene.197,198 Male   vulnerability   may   be   further   enhanced   by   X-linked   
inheritance   of   genetic polymorphisms as both the androgen receptor and the ACE2 genes loci are on 
chromosome X. 
Old age was also associated with an increased risk of infection and worse outcome (Fig. 6). Frailty is 
characterized by multisystem dysregulation leading to reduced physiologic reserve. Although not formally 
assessed in the COVID-19 trials, frailty may be linked to infectious disease through common pathways that 
reduce immunity.199,200 Frailty has also been shown to be associated with poor post-vaccination immune 
response.199 The aged immune system is characterized by a low-grade chronic systemic inflammatory 
state marked by elevated inflammatory markers such as IL- 6 and C-reactive protein and an increased 
susceptibility to infection.201 The expression of ACE2 and TMPRSS2 genes in the type II alveolar cells of 
elderly and young patients is comparable. Therefore, it does not seem to be responsible for the worse 
outcomes observed in COVID-19 affected elderly, but the expression of other receptors is age-
dependent10. 
4.6. Allergy-related risk for COVID-19 
Drug hypersensitivity (11.4%) and urticaria (1.4%) were self-reported by patients with COVID-19.88 In 
contrast, respiratory allergies and asthma were not reported as risk factors for SARS-CoV-2 
infection.84,88,202-205 However, a report from the CDC of U.S. hospitalizations described contradicting 
findings in adults with asthma. Among hospitalized patients with COVID-19, 27.3% of 18-49 year old 
adults had asthma, 13.2% of 50-64 years, and 12.9% of those of 65 years or older.206 Currently, patients 
with allergic rhinitis and patients treated with allergen-specific immunotherapy are advised to continue 
their therapies.207-209
Another study elucidated the impact of comorbid respiratory allergy or asthma on COVID-19 susceptibility 
and disease severity.210 Children with asthma and moderate to severe allergic sensitization showed 
reduced ACE2 gene expression compared to children with non-atopic asthma. An additional trial including 
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challenge. Finally, in vitro experiments using nasal and bronchial airway epithelium showed that IL-13 
reduced the ACE2 expression.210  However, adult patients with asthma seem to have higher expression of 
TMPRSS2 and CD44, which forms a functional complex with CD147 in bronchial epithelium 10.
5. Immunological biomarker profiling of COVID-19 for prediction of disease severity 
The development of serious complications and even fatal outcome in SARS-CoV-2 infection is strongly 
linked to the patients’ immune response resulting in CRS.211 There is an urgent need for biomarkers that 
predict patients developing severe complications.212 To date there is limited information on the 
biomarkers associated with, or even predicting severe complications in COVID-19. However, there is much 
similarity on the biomarkers that have been described before for MERS-CoV and SARS-CoV, also β-
coronaviruses, but also with sepsis. Many markers have been demonstrated to be increased In SARS-CoV-
2 infected individuals. These markers are related to innate as well as adaptive immunity, endothelial cell 
activation, thrombocyte activation and leukocyte infiltration.204 The list of markers related to severe 
disease, ICU and even lethality is more limited. In ICU-admitted COVID-19 patients, significant increases of 
D-dimer, ferritin, LDH, IL-6, high sensitivity cardiac troponin, IL-2, IL-7, G-CSF, MCP-1, MIP-1α and TNF-α 
were reported.204 An even more restricted group of markers (IL-10, MCP-3, IL-1ra) were increased  in 
severe and lethal cases.213 Differences in the biomarkers described are most probably due to the different 
sampling time during disease and the large heterogeneity between the patients.204 
Most likely, single biomarkers will not be predictive. On the other hand, a combination of markers (a 
biosignature) will help in patient stratification and may even guide patients-tailored therapy. 
6. Urgent research needs for mechanistic, diagnostic approaches, therapeutic and preventive insight
6.1. Kids versus adults: mechanisms explaining the clinical differences 
Children experience milder COVID-19 as compared to adults, and a larger proportion of children remains 
asymptomatic (Fig. 6).206 Data from the USA show a strikingly low number of paediatric hospitalizations 
(5.7%) and very limited ICU admissions in young age. 206 Of note, children show similar chest CT results as 
compared to adults, with subpleural ground-glass opacities even when having few symptoms.214 Whilst 
children may be asymptomatic, they are shedding viral particles and can therefore still be contagious with 
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indicating that Th1/Th2 balance may significantly influence course of SARS-CoV-2 infection.210 Therefore, 
type 1 IFNs driving anti-viral immunity may paradoxically promote SARS-CoV-2 expansion by upregulating 
ACE2 expression. Inflammatory responses differ throughout life, for example pre-existing chronic 
inflammation is common in elderly while absent in children. In addition, children have less potent PAMP 
activation, suboptimal, and Th2-skewed cytokine production, all resulting a hypo-inflammatory immune 
response.216 This confers decreased protection against infections, but seem beneficial in preventing a CRS 
in SARS-CoV-2 infection. Hence, preferential Th2-skewed cytokine production observed in children is 
presumably protective (Fig. 6). Additionally, children have less often comorbidities such hypertension, 
diabetes and COPD. However, in rare cases, a severe hyperinflammatory shock syndrome with features of 
atypical Kawasaki disease or toxic shock syndrome was reported in paediatric COVID-19 patients 217, which 
is currently intensively investigated 218.  Data are lacking on evidence surrounding transmission rates of 
the virus by children. The China/World Health Organization joint commission found that infected children 
were largely identified through contact tracing in households of adults 219. However, no significantly 
different virus levels in the respiratory tract were recently reported across age groups, thus having the 
potential for similar transmission rates 57. Understanding the mechanisms underlying different prognosis 
in children is essential for designing targeted therapies for COVID-19. 
6.2. Immunological diagnosis of SARS-CoV-2 infection: challenges of current approaches 
PCR tests are useful for detecting SARS-CoV-2 RNA in an upper respiratory (preferably a nasopharyngeal) 
specimens. In addition, a number of diagnostic procedures to assess immunity built against SARS-CoV-2 
are still being developed, validated and optimized.
Antibody testing is evolving, and the market is flooded with test kits (both ELISA and rapid tests in the 
form of lateral flow immunoassays). However, only a small number of these kits are certified, and the 
results need to be interpreted with caution. Preliminary data indicate that COVID-19 presents with a 
classical antibody response consisting of early induction of IgM, followed by IgA and IgG antibodies (Fig. 
7).131 IgG seems to appear early in the course of clinical presentation probably due to the relatively long 
incubation period. However, there is not yet enough evidence with regard to the development of long-
term protective immunity. Antibody testing is so far more valuable in mapping the situation in individual 
populations, as planned by the WHO in the Solidarity II project.220 Test kits for the assessment of SARS-
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6.3. Immunological treatment approaches: biologicals, small molecules and beyond 
Current evidence on the role of biologicals, small molecules, and passive immunizations in the treatment 
of COVID-19 was assessed conducting a systematic literature search (see online supplement). 
By May 15th, 2020, case series and non-randomized, small, open label studies report on the treatment of 
SARS-CoV 2 infections were assessed. Results from controlled, randomized or placebo-controlled, 
randomized trials are still lacking.  Approaches include either targeting the CRS and hyperinflammatory 
status of lung destruction via anti-IL-6R antibodies,221-240 IL-1R antagonists,241-243 JAK-STAT inhibitors,244 or 
inhibition of entrance by anti CD147 antibodies240 and destruction of the virus via protective antibody 
delivered with convalescent plasma52,55,68,136,137,245 (Table 2). Eculizumab targets complement protein C5 
preventing activation of complement terminal complex, which was used off-label in patients with SARS-
CoV-2 infection and severe pneumonia or ARDS and is now evaluated in an ongoing trail (SOLID-C19).246 
Additionally, clinical trials with type I and III interferons in COVID-19 are currently conducted.247,248 
Targeting T cell exhaustion to reverse the dysfunctional state and restore immune responses can be 
achieved by anti-PD-1 and LAG-3 therapies,249,250 revealing novel therapeutic opportunities for persisting 
infections. In conclusion, prospective, randomized, placebo-controlled trials are needed to elucidate the 
clinical potential of immunomodulatory or passive immunization therapies.
6.4. Virome interactions with commensal communities: future prevention and treatment strategies for 
SARS-CoV-2 infections? 
Mucosal anti-viral immunity can be regulated by the microbiota via multiple mechanisms. The immune 
response to microbes is a form of host defence and entails a variety of intimate interactions with 
important symbiotic physiological effects on the host.251 Specific bacterial components and specific 
metabolites can promote immune maturation and polarization, which ensures appropriate defence 
against occasional pathogens, while strongly promoting immune tolerance networks that dampen 
aberrant inflammatory responses 252,253. The composition of the gut and lung microbiome is strongly 
associated with the induction of polarized immune responses within the human lung.190,253 Bacterial-
derived metabolites such as short chain fatty acids (SCFAs) promote anti-viral responses in the lungs, 
while also reducing inflammation.254,255 Composition and metabolic activity of the gut microbiome has 
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microbial diagnostics with traditional immunological biomarkers will improve patient´s stratification and 
prognosis. In addition, the combination of microbial-derived therapeutics with immune modifying drugs, 
such as biologicals, will enhance response to treatment and better protect from damaging inflammatory 
processes.
6.5. Future pandemic prevention strategies based on immunological knowledge 
Apart from the well-known measures of social distancing, washing hands and disinfection, which have 
proven to limit the SARS-CoV-2 spread, several prevention strategies can be considered from an 
immunological point of view. The WHO Strategic and Technical Advisory Group for Infectious Hazards 
(STAG-IH) regularly reviews and updates its risk assessment of COVID-19 to make recommendations.257 
For the future, it is essential to define the actual prevalence of COVID-19 in the population. Confirmation 
of infection at present consists of PCR for acute infection and serological tests to identify antibodies.258 
However, this may not be sufficient. The implementation of immune tests detecting neutralizing 
antibodies is key to define protection against SARS-CoV-2 (Fig 7). This can only be achieved by 
implementing massive testing. Moreover, multiple vaccines are under development with the aim of 
preventing infection, reducing disease severity and viral shedding. A complete and continually updated 
list is available from the WHO.259,260
Zoonotic infectious diseases have been an important concern to humankind for more than 10,000 years. 
Today, approximately 75% of newly emerging infectious diseases (EIDs) are zoonoses that result from 
various anthropogenic, genetic, ecologic, socioeconomic, and climatic factors. The COVID-19 pandemic is 
an extreme reminder of the role which animal reservoirs play in public health. Also, it reinforces the 
urgent need for globally operationalizing a One Health approach focusing on a broad surveillance for 
SARS-CoV-2 among different animals, and the possibility of reverse zoonosis.261 Moreover, the current 
pandemic highlights the essential need for a broad understanding of immunological mechanisms 
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Tables 
Table 1. Summary of knowledge gaps and research needs pertaining to SARS-CoV-2 and COVID-19 (as of 
May 20, 2020).
Knowledge Gaps Research Needs
Origin and evolution SARS-CoV-2 To shed light on the origin of SARS-CoV-2 via studies of genomic epidemiology 
and evolutionary dynamics 
COVID-19 diagnosis To develop rapid and specific point-of-care diagnostic test for COVID-19 and 
to validate existing serological tests
Zoonotic transmission and 
exhaustive characterization of 
human SARS CoV-2 transmission 
To elucidate mechanisms of SARS-CoV-2 transmission from animals to 
humans and vice versa. To determine how demographic factors and severity 
of COVID-19 patients affect SARS-CoV-2 transmission as well as how 
infectious asymptomatic or pre-symptomatic infected people are
Route of SARS-CoV-2 
transmission
To ascertain the role of fecal–oral transmission in COVID-19 and better define 
the presence and duration of SARS-CoV-2 in oral and respiratory secretions, in 
fecal samples and in serum.
Natural history of asymptomatic 
and mild SARS-CoV-2 infection in 
humans
To identify SARS-CoV-2 a-/oligosymptomatic carriers to track their viral loads, 
clinical presentations and immune response (antibody titers, immune 
phenotyping, etc.) over time
Pathogenicity of SARS-CoV-2
To investigate mechanisms of and changes in SARS-CoV-2 pathogenicity  (as 
compared to SARS-CoV) to provide the basis for the identification of novel 
therapeutic targets
Spectrum of COVID-19 severity To characterize the heterogeneity of COVID-19 severity to aid in directing 
management and treatment of COVID-19 patients
Risk factors and biomarkers 
associated with severe illness or 
mortality in COVID-19
To identify COVID-19 sensitive groups and determine the causes underlying 
disease severity to reinforce prevention strategies and treatment of high-risk 
groups
COVID-19 treatment To screen new pharmaceuticals, small molecule compounds, biologics, and 
other agents that have potent anti-SARS-CoV-2 to empower current COVID-19 
treatments
Vaccine development for SARS-
CoV-2
To develop SARS-CoV-2 vaccines for prevention and ultimate eradication of 
SARS-CoV-2.  Particular attention should be placed to investigate potential 
antibody-dependent enhancement of viral infection in vaccine candidates
Pre-clinical models for SARS-CoV-
2 and COVID-19 research
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Para-/post-infectious syndromes 
in SARS-CoV-2 infection
To understand COVID-19 associated Kawasaki-like syndrome /TSS in children 
and rare para-/post-infectious symptoms in adults.  
Long-term sequelae of COVID-19 Follow-up of COVID patients to detect potential long-term consequences of 
COVID-19 pneumonia (e.g. pulmonary fibrosis, early COPD) and other 
manifestations (e.g. renal impairment, cardiac / vascular dysfunction, 
increased risk of thrombosis / sepsis (due to endothelial dysfunction))  
Individual protection after SARS-
CoV-2 infections
To understand why development of protective antibodies is not seen in all 
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Table 2. Novel immunological treatment options for COVID-19 (as of May 15, 2020)








Intervention Key Information (type of 
























n = 21, prospective, 
open label, non-




Improvement of clinical s
ymptoms:
15/21 lower oxygen dem
and; 
1/21 no oxygen demand 
improvement CT (19/21), 
19/21 discharge at 13.5 d 
after treatment start 
no AE related to drug rep
orted 




























n = 4/33 tocilizumab 
treatment, single center 
prospective 
observational cohort
9/33 discharged ICU, 1 
died, 23 in ICU
Outcome of Tocilizumab 
treated patients not 
disclosed
























n (45), bolus 
n = 14/68 hospitalized 
received tocilizumab, 
retrospective study, 
6/41 and 8/27 received 
tocilizumab



































n = 4 - 2 
doses; 
n = 1 - 3 
doses.
ICU, 5 improvement, 2 
discharged.





















d10: 2 doses 
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12h apart
n = 3, case report
#1 d12 hospitalization, 
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case report #2
Initial improvement, then 
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the symptoms day 9)
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mAb 
IgG1 














(20mg to 80 
b.i.d.); 




Outcomes: 3/4 (criticial 
receiving one dose) died, 
4th persistence of CRP 
elevation over weeks
IL-6 decreased in 10/15 
patients, increased in 4 
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n = 62 TCZ/Co, single 
center, retrospective, 
observational study 
Survival rate significantly 
higher in tocilizumab-
treated patients (60/62) 
as compared to controls 
(12/23) (HR 0.035)
92% of discharged 
patients recovered in 
Tocilizumab. Respiratory 
function improved in 
64.8%
42% of discharged 
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80 mg) for 
10 days
N=91 SOC vs. N=21 TCZ
Retrospective registry 
analysis
No difference regarding 
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n = 45, retrospective 
case-control study: 
n = 20 (TCZ, off label) to 
n=25 (no  TCZ)
p = 0.002; 25% vs 72% 
combined death and/or 
ICU admission endpoint;
p < 0.001; 0% vs 44% ICU 
admission for n = 20
Klopfen-









































n = 3, case series
All with IL-6 decrease and 
CT improvement, no 
adverse effects
#1 fever resolved in 2 
days and oxygen high 
flow nasal cannula 
progressive decrease, 
stopped d12
#2 worsening SpO2 lead 
to Venturi mask d2. d8 
fever gone and oxygen 
stopped
#3 fever resolved d8, 





























COVID-19; b)  
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c) at least 3 of 
the following: 




D-dimer x 10 
normal values; 
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kg) or s.c. 
(324 mg); a 
second 
administrati
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18/63              
(28.6%)
Pilot prospective open, 
single-arm multicentre 
study.  Patients were 
prospectively followed 
for, at least, 14 days after 
admission.
Route of administration 
did not significantly affect 
mortality: 12.9% (4/31) 
and 10.3% (3/29) in the 
tocilizumab i.v. and s.c. 
groups, OR 1.16).
Tocilizumab treatment  
within 6 days from 
admission was associated 
with an increased 
likelihood of survival ad 





































































58% clinical and resp. 
improvement within 24-
72h




stabilization 77%; 15% 
discharged
23% worsening 20% died
 
N=43 in ICU with 
mechanical ventilation, 
32 (74%) improved 17 off 
ventilator 
1 (2%) remained stable 
(BCRSS class 5) 

































n = 3/32, report, realtime 
cohort study
17 remain on ECMO, 10 
died prior or shortly after 
decanunlation, 5 
extubated, 1 of the 5 
discharged (9 doses 
remdesivir). All 5 only on 
v.v. ECMO
2/3 on Tocilizumab 
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19.3) since 








none (n=3) low 
flow nasal 
cannula (n=2), 































randomized, single arm 
study with a 
retrospective control 
group 
10/10: SARS-CoV-2 RNA 
load negative
serum neutralizing 
antibodies 9/10 1:640 (all 
9 had pre-exisitng 
neutralizing antibodies); 
1/10 unavailable
Compared to historic 
control:
CP group: 3/10 
discharged 7/10 
improved status 
Control group: 3/10 










10, 19, 20, 20 
and 22 days 
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n = 5, case series
ARDS resolved in 4/5 
within 12d
3 dismissed (51-55 d post 
infusion)
2 stable, on mechanical 
ventilation (d37 post 
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n = 4, case series 




N= 3 discharged d24-33 
post first CP application. 
N=1 discharged from ICU 
d35 post first CP 
application
Not clear whether effect 















































n = 2, case reports
#1 d22 CP
#2 d7 CP
No adverse reaction to 
plasma, radiological and 
symptom improvement 
# 1 tracheostomy, off 
ventilation now, SARS-
CoV-2 RNA load negative 
d26; #2 1 dicharged d24 
post infusion; SARS-CoV-2 
RNA load negative d20
Ahn JY et 
al. 137

























n = 12, pilot study; open 
label prospective, non-
randomized, single arm 




hydroxychloroquine)     
Outcomes: resolution of 
cough, dyspnea, within 
14 days vs 9/12 and 8/12 
in control group
discharge from hospital 
























n = 17, clinical trial; open 
label prospective, 
concurrent controlled (n 
= 11) for 28 days
All previously treated 
with lopinavir/ritonavir 























11/11 in control 
group)
Comorbidities 





1,2,5 i.v. for 
11 patients, 
6 had 2 
doses only.
and -2b.
Outcomes: shorter time 
to discharge treatment vs 
control (p=0.006); case 
severity improved  
(p=0.021); shorter time to 
virus negative (p=0.014).












































N=1 acute resp. failure 6h 
after first dose (authors 
found no evidence of 
linkage to Anakinra) and 
stopped thereafter and 
ICU admission.
Slow reduction of CRP 
over time and 
normalization in 5/8 at 
day 11
8/11 no fever d3
Reduction of affected 
areas in CT scan (d5-8)












n = 7; i.v. 
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n = 8, case series, non 
randomized, no placebo
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3 died from refractory 
shock (no evidence of 
linkage to anakinra)
n = 1, ventilation 
prevented, discharged 
d18
All with respiratory 
function improved, 



















































HDA vs ST: Survival rate 
d21 high dose Anakinra 
significantly higher (90% 
vs 56%)
HDA vs ST: Mechanical 
ventilation free survivial 
rate d21 (72% vs 50%; not 
significant)
HDA: n=7 discontinuation 
for adverse events d9 
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N=4 (vs ST n=2) 
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Figure legends
Figure 1. SARS-CoV-2 on the animal-human interphase. Animal models that resemble clinical and 
pathological features of COVID-19 are essential to investigate pathogenesis, transmission and therapeutic 
strategies. SARS-CoV-2 shares 96.2% of its genome sequence with the bat CoV RaTG13 posing the bat as 
the most probable natural host of virus origin. SARS-CoV-2 related coronaviruses have been identified in 
Malayan pangolins, which is considered as an intermediate host between bats and humans.  ACE2, a 
critical SARS-CoV-2 receptor, in wild-type mice differs from the human one, therefore transgenic mice 
models with recombinant hACE2 are necessary. To this date, Rhesus macaques, with ACE2 identical to 
human’s, have been used to study the natural course of the disease and the effectiveness of therapeutic 
intervention with intravenous immunoglobulins. Ferrets and cats have been shown susceptible to SARS-
CoV-2 infection and to develop COVID-19 symptoms including respiratory and gastrointestinal 
manifestations. Limited facilities and expertise in handling non-murine species may hamper usage of the 
aforementioned models. Transmission between human and animals has not been unequivocally 
confirmed.
Figure 2. Cellular distribution of confirmed and potential SARS-CoV-2 receptors and interaction 
partners. Entry of SARS-CoV-2 into the host cells depends on expression of i) adequate receptors and ii) 
cellular proteases. The two-step infection process is mediated by the viral Spike (S) protein. Its binding to 
the receptor and cleavage by proteases assures virus internalization. ACE2 and TMPRSS2 are critical 
complex for SARS-CoV-2 infection. CD147 and its extracellular (Cyclophilin A, Cyclophilin B, Platelet 
glycoprotein VI, S100A9, Hyaluronic acid) and transmembrane (CD44, Syndecan-1) interaction partners 
can be also used for SARS-CoV-2 entry and/or modulation of immune responses to the virus. It has been 
suggested for SARS-CoV-2 and shown in case of other Coronavidae family members that they can also 
exploit other cell surface receptors (CD26, ANPEP, ENPEP, DC-SIGN) and proteases (Furin, Cathepsin L, 
Cathepsin) to enter human cells.  CypA, Cyclophilin A; CypB, Cyclophilin B; GPVI, Platelet glycoprotein VI; 
HA, Hyaluronic acid; SYND1, Syndecan-1. This figure is modified from the original publication by 
Radzikowska, Ding, et al., presenting the distribution of these receptors in various human tissues and 
immune cells in healthy children and adults, and in patients with COVID-19 comorbidities and risk factors 
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Figure 3. Epithelial barriers are susceptible for the SARS-CoV-2 infection. (A) Epithelial cells of the 
respiratory system are the primary site of SARS-CoV-2 infection. The respiratory epithelium is equipped 
with the receptors and other host proteins allowing viral entry: ACE2, TMPRSS2, CD147 and CD26. The 
highest expression of ACE2 is found in the nasopharynx. The virus was found to propagate in the lower 
respiratory tract as well, especially in type II alveolar cells.  The effects of the virus on the respiratory 
epithelial barrier include: cell membrane fusion and syncytium formation (which represents a mechanism 
of viral spread), apoptosis and virus-mediated cell lysis leading to the loss of barrier function. Upon 
infection, epithelial cells release interferons, chemokines and cytokines promoting tissue infiltration by 
innate immune cells, such as monocytes, NK cells, neutrophils and, with time, inflammatory macrophages 
and virus-specific lymphocytes. Immune cells express putative SARS-CoV-2 receptors, CD147 and CD26. 
(B) Gastrointestinal symptoms are seen in a substantial percentage of COVID-19 patients. The intestinal 
tissue has a high expression of ACE2 receptor, TMPRSS2 and TMPRSS4 proteases. Their expression 
increases with intestinal epithelial cell differentiation. ACE2 expression in intestinal epithelium decreases 
with inflammation and shows a negative correlation with IL-1β levels. SARS-CoV-2 infection results in 
disintegration of the intestinal epithelial barrier. Virus-specific IgA have been found in the gastrointestinal 
tract. Non-infectious SARS-CoV-2 RNA is found in stool after negative nasal swab tests. CXCL10, C-X-C 
motif chemokine 10; CXCR1, C-X-C motif chemokine receptor 1; CXCR10, C-X-C motif chemokine receptor 
10; GB, goblet cell; ILC, innate lymphoid cell; IL, interleukin; IFN, interferon; Mθ, macrophage; MO, 
monocyte; NEU, neutrophil; NK, natural killer cell; pDC, plasmacytoid dendritic cell; TNF, tumor necrosis 
factor
Figure 4. Immunology of adequate and non-adequate response to SARS-CoV-2 infection. The clinical 
course of the SARS-CoV-2 infection varies from an asymptomatic to a severe, life-threatening syndrome. 
The number of asymptomatic carriers is unknown and virus detection is often accidental. Data on the 
immune characteristics in this group are lacking. Patients who experience mild symptoms are 
characterized by a transient, slight decrease in lymphocyte counts and an increase in neutrophil counts in 
the peripheral blood. Viral clearance in this group is convergent in time with the specific antibody 
production. Delayed and limited IFN type I response in combination with the overactivation of 
proinflammatory cytokine response has been suggested as a possible mechanistic explanation of 
hyperinflammatory syndrome in COVID-19 patients presenting with severe clinical manifestations: 
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characterized by a systemic cytokine release syndrome (CRS), increased levels of LDH and CRP, 
hypoalbuminemia, deepening decrease in lymphocyte counts and immune exhaustion of T cells. 
Figure 5. Involvement of endothelium in COVID-19 progression. 
SARS-CoV-2 viremia is seen approximately 1 week after the onset of illness, accompanied by an 
abundance of circulating proinflammatory cytokines. Endothelial cells express ACE2 receptor and can be 
infected by the SARS-CoV-2. Direct viral influence on the endothelial cells, as well as systemic 
inflammation (depicted by activated neutrophils and extensive NET-osis) and cytokine storm, can lead to 
endotheliitis, disseminated intravascular coagulation and coagulopathy, described in severely affected 
COVID-19 patients. Activated endothelial cells upregulate the expression of adhesion molecules (P-
selectin) and coagulation factors (vWF), secrete immune mediators (CCL2, IL-6). Monocytes respond to 
these by releasing tissue factor and upregulate the expression of PSGL. Simultaneously, platelet activation 
and aggregation occurs. Increased numbers of neutrophils and monocytes in the peripheral blood 
correlate with severe disease course and fatalities. CCL2, CC-chemokine ligand; IL-6, interleukin 6; MO, 
monocyte; NEU, neutrophil; NET, neutrophil extracellular traps; PLT, platelets; PSGL, P-selectin 
glycoprotein ligand 1; vWF von Willebrand factor.
Figure 6. Age, gender and comorbidities modify the onset and progression of COVID-19. Epidemiological 
observations show clear differences in the course of SARS-CoV-2 infection between children and adults. It 
seems that children are less susceptible to the infection and develop less typical symptoms of the disease. 
Consequences of the infection on physiological development of children are unknown. Clinical data and 
age-related rhesus macaque model of COVID-19 reveal that obesity, diabetes, hypertension, smoking, 
chronic respiratory diseases, male gender and older age are the most common risk factors for 
development of severe COVID-19. Older age is associated with higher incidence of multimorbidity and 
state of low-grade systemic inflammation. Immunosenescence could influence the adequacy of the host’s 
response to the infection.
Figure 7. Clinical stages of COVID-19 and their virology and immunological assessment. The success of 
restraining SARS-CoV-2 transmission depends on accurate and timely diagnostics. Asymptomatic patients 
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are currently the golden standard in the initial phase of the infection. Viral antigens can be detected in 
patients’ blood by means of ELISA tests. ELISA tests allow for detection of virus-specific antibodies in 
patients’ serum. The production of specific IgM starts after about a week from infection and IgM levels 
decrease with the production of specific IgG (after about 2 weeks from infection). Novel diagnostic and 
risk-stratification strategies could include microbiome profiling and tests detecting neutralizing 
antibodies. 
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